• 1
    Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1:1120.
  • 2
    Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommn Rep 2010; 59:127.
  • 3
    Centers for Disease Control and Prevention. CDC health information for international travel 2014. New York: Oxford University Press, 2014.
  • 4
    Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26:60776082.
  • 5
    Monath TH, Cetron MS, Teuwen D. Yellow fever. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. Philadelphia: Saunders/Elsevier, 2008:9591055.
  • 6
    Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358:121122.
  • 7
    Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358:98104.
  • 8
    Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358:9197.
  • 9
    Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30:50385058.
  • 10
    Thomas RE, Spragins W, Lorenzetti DL. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria? Vaccine 2013; 31:62016209.
  • 11
    Engel AR, Vasconcelos PFC, McArthur MA, Barrett AD. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006; 24:28032809.
  • 12
    Khromova AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as risk factor for serious adverse events. Vaccine 2005; 23:32563263.
  • 13
    Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17 D yellow fever vaccine, ARILVAX. Vaccine 2004; 22:21032105.
  • 14
    Martin M, Weld LH, Tsai TF, et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7:945951.
  • 15
    Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell Q Rep 2004; 28:244248.
  • 16
    Barwick R. History of thymoma and yellow fever vaccination. Lancet 2004; 36:936.
  • 17
    Whittembury A, Ramirez G, Hernández H, Repero AM, et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009; 27:59745981.
  • 18
    Reinhardt B, Jaspert R, Niedrig M, et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56:159167.
  • 19
    Dos Santos AP, Bertho AL, Dias DC, et al. Lymphocyte subset analysis in healthy adults vaccinated with yellow fever 17DD virus. Mem Inst Oswaldo Cruz 2005; 100:331337.
  • 20
    Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007; 25:84808485.